Lifestyle-related disorders such as cardiovascular disease and diabetes are rising rapidly across India, creating sustained demand for long-term medication. This has made partnering with a reliable cardiac diabetic PCD franchise company one of the most stable and scalable opportunities in the pharmaceutical sector.
Cardiac and diabetic medicines are typically prescribed for chronic use, resulting in consistent demand, strong repeat prescriptions, and long-term patient adherence. For pharma professionals, distributors, and entrepreneurs, this segment offers predictable growth supported by clinical necessity.
Kroyf Labs offers a professionally structured cardiac diabetic PCD franchise company model in India, combining premium-quality formulations, regulatory compliance, and exclusive monopoly rights to support sustainable business expansion.
| Sr.No. | Brand Name | Dosage Form | Composition | Pack |
|---|---|---|---|---|
| 1 | Glimsee M1 | Tablet | Glimepiride 1 mg+ Metformin 500 SR mg (Bilayered) | 10*10 BLI |
| 2 | Glimsee M2 | Tablet | Glimepiride 2 mg+ Metformin 500 SR mg (Bilayered) | 10*10 BLI |
| 3 | Glimsee MV1 0.2 | Tablet | Glimepiride 1 mg + Metformin 500 mg + Voglibose 0.2 mg (Bilayered) | 10*10 BLI |
| 4 | Glimsee MV1 0.3 | Tablet | Glimepiride 1 mg + Metformin 500 mg + Voglibose 0.3 mg (Bilayered) | 10*10 BLI |
| 5 | Glimsee MV2 0.2 | Tablet | Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.2 mg (Bilayered) | 10*10 BLI |
| 6 | Glimsee MV2 0.3 | Tablet | Glimepiride 2 mg + Metformin 500 mg + Voglibose 0.3 mg (Bilayered) | 10*10 BLI |
| 7 | Glimsee PM1 | Tablet | Glimepiride 1 mg+Metformin 500 mg + Pioglitazone 15 mg (Bilayered) | 10*10 BLI |
| 8 | Glimsee PM2 | Tablet | Glimepiride2 mg+Metformin 500 mg + Pioglitazone 15 mg (Bilayered) | 10*10 BLI |
| 9 | Dapatest 5 | Tablet | Dapagliflozin 5mg | 10*14 Alu-Alu |
| 10 | Dapatest 10 | Tablet | Dapagliflozin 10mg | 10*14 Alu-Alu |
| 11 | Dapatest M 10/500 | Tablet | Dapagliflozin 10 Mg + Metformin 500 Mg | 10*10 Alu-Alu |
| 12 | Vildopin 50 | Tablet | Vildagliptin 50 mg | 10*15 Alu-Alu |
| 13 | Viltrop DP 100/10 | Tablet | Vildagliptin (SR) 100 mg + Dapagliflozin 10 mg | 10*10 Alu-Alu |
| 14 | Vildopin M 50/500 | Tablet | Vildagliptin 50 mg + Metformin 500 mg | 10*15 Alu-Alu |
| 15 | Glickle M | Tablet | Gliclazide 80mg + Metformin 500mg | 10*10 BLI |
| 16 | Sitaseek M 50/500 | Tablet | Sitagliptin 50 Mg + Metformin 500 Mg | 10*15 Bli |
| 17 | Sitaseek M 50/1000 | Tablet | Sitagliptin 50 Mg + Metformin 1000 Mg | 10*15 Bli |
| 18 | Sitaseek M 100/500 | Tablet | Sitagliptin 100 Mg + Metformin 500 Mg | 10*10 Alu-Alu |
| 19 | Sitaseek M 100/1000 | Tablet | Sitagliptin 100 Mg + Metformin 1000 Mg | 10*10 Alu-Alu |
| 20 | Sitaseek DP 100/10 | Tablet | Sitagliptin 100 mg + Dapagliflozin 10 mg | 10*10 Alu-Alu |
| 21 | Glipcheck 20 | Tablet | Teneligliptin 20mg | 10*10 Alu-Alu |
| 22 | Glipcheck M | Tablet | Teneligliptin 20mg + Metformin 500 mg SR | 10*10 Alu-Alu |
Growing Burden of Cardiac and Diabetic Disorders in India
India faces a significant rise in non-communicable diseases (NCDs). According to the
World Health Organization, cardiovascular diseases and diabetes are among the leading causes of morbidity and mortality globally, with India contributing a substantial share.
WHO highlights that long-term access to quality-assured medicines is critical for managing these chronic conditions effectively.
Reference:
https://www.who.int/health-topics/noncommunicable-diseases
Similarly, the Ministry of Health and Family Welfare (MoHFW) emphasizes early diagnosis and continuous treatment for cardiac and diabetic conditions under national NCD programs.
This sustained medical need makes the cardiac diabetic PCD franchise company model highly resilient and future-ready.
What Is a Cardiac Diabetic PCD Franchise Company?
A cardiac diabetic PCD franchise company allows distributors to market a company’s cardiac and diabetic product portfolio under its brand name within an allotted territory. This model is preferred due to:
-
Monopoly rights in a defined region
-
Ready portfolio of high-demand chronic medicines
-
Lower investment risk compared to own manufacturing
-
Strong doctor and hospital connect
-
Long-term business continuity
Choosing the right cardiac diabetic PCD franchise company ensures access to consistent prescriptions and stable market demand.
Product Categories Covered Under Cardiac Diabetic PCD Franchise
A comprehensive cardiac-diabetic portfolio should address multiple therapeutic needs. A professionally managed cardiac diabetic PCD franchise company typically includes:
Cardiac Range
-
Antihypertensives
-
Antiplatelet and anticoagulant formulations
-
Lipid-lowering agents
-
Cardiac support and adjunct therapies
Diabetic Range
-
Oral antidiabetic agents
-
Combination antidiabetic formulations
-
Neuropathy support medicines
-
Vitamins and metabolic supplements
These products align with standard treatment protocols for chronic disease management.
Regulatory Framework for Cardiac & Diabetic Medicines in India
Cardiac and diabetic medicines are regulated under the Drugs & Cosmetics Act, 1940, and governed by the
Central Drugs Standard Control Organization (CDSCO).
CDSCO ensures:
-
Approval of formulations
-
Manufacturing compliance
-
Quality, safety, and labeling norms
Official portal: https://cdsco.gov.in/opencms/opencms/en/Home/
Manufacturing units supplying cardiac and diabetic medicines must also comply with Good Manufacturing Practices (GMP) as defined by the
World Health Organization.
Quality standards for drug substances and finished formulations are further guided by the
Indian Pharmacopoeia Commission (IPC).
Partnering with a compliant cardiac diabetic PCD franchise company ensures regulatory acceptance and long-term trust.
Why Quality Matters in Cardiac & Diabetic Medicines
Cardiac and diabetic patients rely on medicines for extended or lifelong use. Regulatory authorities stress:
-
Consistent formulation accuracy
-
Bioavailability and stability
-
Batch-to-batch consistency
-
Pharmacovigilance and traceability
According to WHO guidance on chronic disease management, access to quality-assured medicines is essential for preventing complications and improving patient outcomes.
This makes quality-focused manufacturing a decisive factor when selecting a cardiac diabetic PCD franchise company.
Why Choose Kroyf Labs as Your Cardiac Diabetic PCD Franchise Company
Among companies operating as a cardiac diabetic PCD franchise company, Kroyf Labs follows a premium-quality, compliance-driven approach while maintaining partner-friendly pricing.
Many of Kroyf Labs’ cardiac and diabetic formulations are manufactured at facilities that also serve established pharmaceutical brands, ensuring the same regulatory discipline, quality systems, and manufacturing standards — without inflated branding costs.
Key strengths of Kroyf Labs:
-
WHO-GMP compliant manufacturing
-
Broad cardiac and diabetic product portfolio
-
30+ chronic-care focused formulations
-
Competitive pricing with sustainable margins
-
Transparent and ethical business practices
-
Reliable supply chain and professional support
This balance of premium quality and practical business value positions Kroyf Labs as a dependable cardiac diabetic PCD franchise company in India.
Exclusive Monopoly Rights – State & District Level
Kroyf Labs offers exclusive monopoly rights at both state-wise and district-wise levels, allowing partners to operate without internal competition.
Monopoly benefits include:
-
Stronger doctor relationships
-
Confident investment in marketing
-
Improved brand recall
-
Long-term territory control
Territory allocation is done transparently to support structured growth under the cardiac diabetic PCD franchise company model.
Who Can Partner With a Cardiac Diabetic PCD Franchise Company?
This opportunity is ideal for:
-
Pharma distributors
-
Medical representatives
-
Healthcare entrepreneurs
-
Existing PCD franchise holders
-
Pharma companies expanding into chronic care
Given the long-term nature of cardiac and diabetic treatments, this segment offers consistent returns with controlled risk.
Storage, Handling & Quality Assurance
WHO and IPC guidelines emphasize proper storage and handling of chronic medicines to maintain efficacy. Best practices include:
-
Storage in cool, dry conditions
-
Protection from heat and moisture
-
Inventory rotation and traceability
-
Compliance with label instructions
Kroyf Labs follows these protocols to ensure product integrity across its cardiac and diabetic range.
Frequently Asked Questions (FAQs)
What is a cardiac diabetic PCD franchise company?
It is a pharma company that offers cardiac and diabetic medicines to distributors under a PCD model with monopoly rights in a defined territory.
Why is the cardiac-diabetic segment profitable?
Cardiac and diabetic conditions require long-term treatment, resulting in repeat prescriptions, consistent demand, and stable business growth.
Are cardiac and diabetic medicines regulated in India?
Yes. They are regulated by the
Central Drugs Standard Control Organization (CDSCO) under the Drugs & Cosmetics Act, 1940.
https://cdsco.gov.in/opencms/opencms/en/Home/
Why is WHO-GMP important for cardiac-diabetic medicines?
WHO-GMP ensures medicines are manufactured under controlled conditions, ensuring safety, consistency, and quality — especially critical for chronic therapies.
https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/gmp
Does Kroyf Labs offer monopoly-based franchise opportunities?
Yes. Kroyf Labs provides exclusive state-wise and district-wise monopoly rights for its cardiac and diabetic franchise partners.
Start Your Cardiac Diabetic PCD Franchise Company Partnership With Kroyf Labs
If you are looking to associate with a quality-focused, professionally managed cardiac diabetic PCD franchise company, Kroyf Labs offers the right blend of regulatory compliance, premium manufacturing standards, and long-term business support.
With an expanding chronic-care portfolio, exclusive monopoly rights, and a transparent partnership model, we help our associates build stable and scalable pharma businesses across India.
👉 Contact us today to explore franchise availability, product details, and partnership opportunities.
